Merck Stock Dips 033% with 845 Million in Trading Volume Ranking 95th as HPV Vaccine Dosing News Emerges

On May 23, 2025, Merck & Co., Inc. (MRK) experienced a slight decline of 0.33% in its stock price, with a trading volume of $845 million, placing it at the 95th position in terms of trading volume for the day.

Merck has recently issued statements regarding a potential reduced dosing recommendation for its HPV vaccine, GARDASIL®9. The company affirmed its position on alternate dosing regimens for GARDASIL®9, highlighting comparable effectiveness data of a single-dose regimen to the approved three-dose regimen. This development could significantly impact the market dynamics for Merck's HPV vaccine, potentially leading to increased accessibility and affordability for patients.

In the realm of oncology, Merck showcased innovation in advanced cancers, presenting data that supported the selection of a 2.8 mg/kg dose for further development. This dose showed a higher overall response rate and similar safety profile, indicating a promising direction for Merck's cancer treatments.

Additionally, Merck presented positive Phase 2 data for Enpatoran, demonstrating a reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active lupus rash. This data underscores Merck's commitment to advancing therapies for autoimmune diseases, potentially broadening its therapeutic portfolio.